Loading
Cardiovascular Disease and Adiposity / Adipokines, Inflammation, and Metabolic Diseases · Journal article
International Journal of Angiology · July 10, 2026
Reinforces what was already believed, rather than introducing something new.
This narrative and systematic review confirms obesity as a robust cardiometabolic risk factor mediated by metabolic and structural pathways, and synthesizes evidence that semaglutide and tirzepatide reduce weight, improve cardiac function, and lower inflammation markers, with some benefit independent of weight loss. The review notes heterogeneity in the obesity paradox and calls for refinement of obesity phenotype understanding, but does not present new primary data or a formal meta-analysis.
Narrative and systematic review. Studies on obesity and obesity-related cardiovascular disease; specific eligibility criteria not detailed in abstract. Intervention: Semaglutide, tirzepatide, and other anti-obesity pharmacotherapies. Compared with: Comparison groups or control arms of included trials not specified in abstract.
Obesity prevalence exceeds 30% in many regions and substantially contributes to CVD burden Semaglutide, tirzepatide, and other agents demonstrated robust weight reduction and improved functional capacity with cardiac remodeling attenuation Anti-obesity agents lowered inflammation markers and natriuretic peptides, with benefits independent of weight loss
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize obesity as a modifiable cardiometabolic risk factor and consider anti-obesity pharmacotherapy (semaglutide, tirzepatide) as disease-modifying agents for obesity-related heart failure and AF, with potential benefits on inflammation and cardiac remodeling independent of weight loss alone. Future practice should be informed by phenotyping obesity subtypes and accounting for cardiorespiratory fitness.
A narrative and systematic review synthesizing existing clinical trial evidence on obesity and cardiometabolic disease, confirming established associations and summarizing findings on newer anti-obesity agents; not a primary trial or meta-analysis with novel integrated analysis.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize obesity as a modifiable cardiometabolic risk factor and consider anti-obesity pharmacotherapy (semaglutide, tirzepatide) as disease-modifying agents for obesity-related heart failure and AF, with potential benefits on inflammation and cardiac remodeling independent of weight loss alone. Future practice should be informed by phenotyping obesity subtypes and accounting for cardiorespiratory fitness.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Obesity has emerged as one of the most significant health challenges, with prevalence rates exceeding 30% in many regions and contributing substantially to the burden of cardiovascular disease (CVD). This review synthesized findings from clinical trials, systematic reviews, and narrative reviews. Key outcomes assessed included heart failure symptoms, echocardiographic parameters, incidence of atrial fibrillation (AF), inflammation biomarkers, and overall cardiovascular morbidity and mortality. Across studies, obesity was consistently linked with elevated risk of coronary heart disease, AF, stroke, and heart failure with preserved ejection fraction (HFpEF). Central adiposity and ectopic fat depots, especially epicardial fat, emerged as critical mediators of CVD progression. Semaglutide, tirzepatide, and other agents have demonstrated robust effects in reducing weight, improving functional capacity, and attenuating cardiac remodeling, with additional benefits in lowering inflammation markers and natriuretic peptides independent of weight loss. Notably, patients with AF and obesity-related HFpEF appeared to experience greater symptomatic and functional improvements with semaglutide compared with those without AF. Conversely, evidence on the obesity paradox and metabolically healthy obesity revealed heterogeneity, with some subgroups demonstrating preserved or even improved survival despite excess adiposity, though these effects may be confounded by differences in cardiorespiratory fitness and lead time biases. Obesity remains a powerful risk factor for CVD, mediated through both metabolic and structural pathways. The advent of anti-obesity pharmacotherapies represents a watershed moment for cardiology, offering disease-modifying potential in obesity-related heart failure and beyond. Future research should refine the understanding of obesity phenotypes, and the role of fat distribution and cardiorespiratory fitness.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.